Incidence and outcomes of adverse drug reactions to first‐line anti‐tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study. Issue 11 (9th August 2022)
- Record Type:
- Journal Article
- Title:
- Incidence and outcomes of adverse drug reactions to first‐line anti‐tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study. Issue 11 (9th August 2022)
- Main Title:
- Incidence and outcomes of adverse drug reactions to first‐line anti‐tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study
- Authors:
- Choi, Hayoung
Park, Hang A.
Hyun, In Gyu
Kim, Joo‐Hee
Hwang, Yong‐Il
Jang, Seung Hun
Sim, Yun Su
Shin, Tae Rim
Ko, Yousang
Ban, Ga Young
Hong, Ji Young
Lee, Chang Youl
Lee, Myung Goo
Choi, Jeong‐Hee - Abstract:
- Abstract: Background: In tuberculosis (TB) treatment, adverse drug reactions (ADRs) can interrupt treatment and decrease the quality of life (QoL). We aimed to prospectively investigate the incidence of ADRs to first‐line anti‐TB drugs and related outcomes and QoL. Methods: Adult patients with TB who had been treated with first‐line anti‐TB drugs in five Korean hospitals were enrolled. ADR questionnaire surveys and blood tests were performed four times serially, and QoL was assessed on the fourth TB treatment week (±2 weeks). Results: Of 410 enrolled patients with TB (males, 62%; mean age, 52.1 ± 18.1 years [those aged ≥65 years, 26.6%]), 67.8% experienced any ADRs (≥ grade 2) to TB drugs. The most common ADR was fatigue (53.2%), followed by itching (42.7%) and anorexia (41.7%). Older adult patients experienced relatively more ADRs, including anorexia, dyspepsia, rash, dizziness, anemia, abnormal hepatic/renal function tests, and increased uric acid levels ( p < 0.05). Treatment regimens changed for 9.5% of patients owing to ADRs to anti‐TB drugs. Patients with any ADRs and older adult patients had significantly lower QoL than their counterparts ( p < 0.05). Old age (odds ratio [OR], 1.02) and being male (OR 2.65) were independently associated with ADRs, whereas active smoking (OR 4.73) and a relatively long treatment phase (OR 5.13) were independently associated with hepatotoxicity. Conclusion: ADRs to first‐line anti‐TB drugs were common and related to relatively lowAbstract: Background: In tuberculosis (TB) treatment, adverse drug reactions (ADRs) can interrupt treatment and decrease the quality of life (QoL). We aimed to prospectively investigate the incidence of ADRs to first‐line anti‐TB drugs and related outcomes and QoL. Methods: Adult patients with TB who had been treated with first‐line anti‐TB drugs in five Korean hospitals were enrolled. ADR questionnaire surveys and blood tests were performed four times serially, and QoL was assessed on the fourth TB treatment week (±2 weeks). Results: Of 410 enrolled patients with TB (males, 62%; mean age, 52.1 ± 18.1 years [those aged ≥65 years, 26.6%]), 67.8% experienced any ADRs (≥ grade 2) to TB drugs. The most common ADR was fatigue (53.2%), followed by itching (42.7%) and anorexia (41.7%). Older adult patients experienced relatively more ADRs, including anorexia, dyspepsia, rash, dizziness, anemia, abnormal hepatic/renal function tests, and increased uric acid levels ( p < 0.05). Treatment regimens changed for 9.5% of patients owing to ADRs to anti‐TB drugs. Patients with any ADRs and older adult patients had significantly lower QoL than their counterparts ( p < 0.05). Old age (odds ratio [OR], 1.02) and being male (OR 2.65) were independently associated with ADRs, whereas active smoking (OR 4.73) and a relatively long treatment phase (OR 5.13) were independently associated with hepatotoxicity. Conclusion: ADRs to first‐line anti‐TB drugs were common and related to relatively low QoL, especially among older adults. Although 9.5% of patients had ADR‐related regimen changes, most patients with ADRs completed treatments successfully. … (more)
- Is Part Of:
- Pharmacoepidemiology and drug safety. Volume 31:Issue 11(2022)
- Journal:
- Pharmacoepidemiology and drug safety
- Issue:
- Volume 31:Issue 11(2022)
- Issue Display:
- Volume 31, Issue 11 (2022)
- Year:
- 2022
- Volume:
- 31
- Issue:
- 11
- Issue Sort Value:
- 2022-0031-0011-0000
- Page Start:
- 1153
- Page End:
- 1163
- Publication Date:
- 2022-08-09
- Subjects:
- adverse drug reactions -- ant‐tuberculosis drugs -- incidence -- outcomes -- quality of life
Pharmacoepidemiology -- Periodicals
Chemotherapy -- Periodicals
Epidemiology -- Periodicals
615.705 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/pds.5513 ↗
- Languages:
- English
- ISSNs:
- 1053-8569
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.248000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24310.xml